ID: ALA3357928

Max Phase: Preclinical

Molecular Formula: C16H18N4O11

Molecular Weight: 442.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)OC[C@@H]1O[C@@H](n2c(=O)n(C)c(=O)c3c2no[n+]3[O-])[C@H](OC(C)=O)[C@H]1OC(C)=O

Standard InChI:  InChI=1S/C16H18N4O11/c1-6(21)27-5-9-11(28-7(2)22)12(29-8(3)23)15(30-9)19-13-10(20(26)31-17-13)14(24)18(4)16(19)25/h9,11-12,15H,5H2,1-4H3/t9-,11-,12+,15+/m0/s1

Standard InChI Key:  KGSCIIDDEHESJX-APAOZMKASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 442.34

Molecular Weight (Monoisotopic): 442.0972

AlogP: -2.35

#Rotatable Bonds: 5

Polar Surface Area: 185.10

Molecular Species: NEUTRAL

HBA: 14

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 15

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: -2.76

CX LogD: -2.76

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.27

Np Likeness Score: 0.64

References

1. Xu X, Wang J, Yao Q..  (2015)  Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents.,  25  (2): [PMID:25515560] [10.1016/j.bmcl.2014.11.065]

Source

Source(1):

• Scientific Literature